Reference Interval:
| Test Number
| Components
| Reference Interval
| | | Neuronal Nuclear Antibody (ANNA) IgG Screen, by IFA
| < 1:10
| | 0050892 | Neuronal Nuclear Antibody (ANNA) Reflex IFA Titer, IgG
| < 1:10 No antibody detected
| | 0051088 | Neuronal Nuclear Antibodies (ANNA) IgG, Immunoblot, Serum
| | Test Number
| Components
| Reference Interval
| | | Neuronal Nuclear Antibody IgG, Immunoblot Anti-Hu
| Refer to test 0051147 | | | Neuronal Nuclear Antibody IgG, Immunoblot Anti-Ri
| Refer to test 0051148 |
|
|
| Interpretive Data: |
ANNA-1 (anti-Hu) and ANNA-2 (anti-Ri) are screened by immunofluorescence and confirmed by immunoblot detection of antibody reactive with a 35-40 kDa (ANNA-1) or a 55 kDa (ANNA-2) neuronal protein. ANNA-1 is present in patients with paraneoplastic syndromes (paraneoplastic sensory neuropathy or paraneoplastic encephalomyelitis) most commonly associated with small-cell lung carcinoma (SCLC). ANNA-2 is present in patients with midbrain encephalitis, cerebellar ataxia, eye movement disorders (usually opsoclonus), and occasionally myelopathy. Neoplasms most often associated with ANNA-2 are breast carcinoma and SCLC. ANNA-1 and ANNA-2 may be detectable before the associated neoplasm is detectable.
ANNA antibodies are screened by IFA. If the IFA screen shows reactivity at 1:10, the sample will be titered to endpoint and confirmed (Hu or Ri) by immunoblot.
Please refer to Statement D in the Compliance Statements section in the front of the Laboratory Test Directory.
|
| Note: |
ANNA antibodies are screened by IFA. If the IFA screen is 1:10, then a titer and immunoblot (Hu and Ri) will be added.
|
| CPT Code(s): |
86255 ANNA; if reflexed, add 86256 ANNA titer and 83516 Immunoblot
|
|